{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T23:25:37Z","timestamp":1774308337677,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In mildly to moderately dehydrated patients with acute gastroenteritis (AGE), oral rehydration therapy (ORT) is the treatment of choice. Though ondansetron is a very effective antiemetics and leads to succeed ORT, there have been reports QT prolongation in patients using it. We investigated the effect of oral ondansetron on QT interval in mildly to moderately dehydrated children with AGE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective observational study was conducted in a single pediatric emergency department (ED) of a tertiary university hospital. We collected the medical records of patients with a primary diagnosis of AGE who received oral ondansetron and underwent an electrocardiogram between January 2017 and June 2018. A pediatric emergency physician calculated the corrected QT interval (QTc) by Bazett\u2019s method, and the calculations were reviewed by a pediatric cardiologist. QTc values before (preQTc) and after (postQTc) ondansetron administration were analyzed. \u0394QTc was calculated as the change from preQTc to postQTc. We also investigated any cardiac complications from oral ondansetron.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Total 80 patients were included. The mean age of the patients was 53.31\u2009\u00b1\u200932.42\u2009months, and 45% were male. The mean dose of oral ondansetron was 0.18\u2009\u00b1\u20090.04\u2009mg\/kg. The mean interval from administration of ondansetron to performance of the electrocardiogram was 65\u2009\u00b1\u00a026\u2009min. The mean preQTc was 403.3\u2009\u00b1\u200924.0\u2009ms, and the mean postQTc was 407.2\u2009\u00b1\u200926.7\u2009ms. Two patients had a preQTc \u2265460\u2009ms, and one patient had a postQTc \u2265460\u2009ms. \u0394QTc was \u226530\u2009ms in seven patients (8.8%). No \u0394QTc was \u226560\u2009ms. No pre- or postQTc was \u2265500\u2009ms. No patient had a fatal cardiac arrhythmia after taking ondansetron.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Oral administration of a single dose of ondansetron in children with AGE did not cause high-risk QTc prolongation or fatal arrhythmia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-021-02937-0","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T08:04:09Z","timestamp":1636531449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The effect of oral ondansetron on QT interval in children with acute gastroenteritis; a retrospective observational study"],"prefix":"10.1186","volume":"21","author":[{"given":"Heewon","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woochan","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yura","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sooin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jisook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"2937_CR1","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","volume":"388","author":"GBD 2015 Mortality and Causes of Death Collaborators","year":"2016","unstructured":"GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459\u2013544.","journal-title":"Lancet"},{"key":"2937_CR2","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1056\/NEJMoa055119","volume":"354","author":"SB Freedman","year":"2006","unstructured":"Freedman SB, Adler M, Seshadri R, Powell EC. Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med. 2006;354:1698\u2013705.","journal-title":"N Engl J Med"},{"key":"2937_CR3","doi-asserted-by":"crossref","unstructured":"Freedman SB, Steiner MJ, Chan KJ. Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis. PLoS Med. 2010;7(10):e1000350.","DOI":"10.1371\/journal.pmed.1000350"},{"issue":"4","key":"2937_CR4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-4310","volume":"140","author":"L Rutman","year":"2017","unstructured":"Rutman L, Klein EJ, Brown JC. Clinical pathway produces sustained improvement in acute gastroenteritis care. Pediatrics. 2017;140(4):e20164310.","journal-title":"Pediatrics."},{"key":"2937_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpeds.2015.10.006","volume":"169","author":"AS Danewa","year":"2016","unstructured":"Danewa AS, Shah D, Batra P, Bhattacharya SK, Gupta P. Oral Ondansetron in Management of Dehydrating Diarrhea with vomiting in children aged 3 months to 5 years: a randomized controlled trial. J Pediatr. 2016;169:105\u20139 e3.","journal-title":"J Pediatr"},{"key":"2937_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2165\/11537770-000000000-00000","volume":"12","author":"SB Freedman","year":"2010","unstructured":"Freedman SB, Powell EC, Nava-Ocampo AA, Finkelstein Y. Ondansetron dosing in pediatric gastroenteritis: a prospective cohort, dose-response study. Paediatr Drugs. 2010;12:405\u201310.","journal-title":"Paediatr Drugs"},{"key":"2937_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165441","volume":"11","author":"F Marchetti","year":"2016","unstructured":"Marchetti F, Bonati M, Maestro A, Zanon D, Rovere F, Arrighini A, et al. Oral Ondansetron versus Domperidone for acute gastroenteritis in pediatric emergency departments: multicenter double blind randomized controlled trial. PLoS One. 2016;11:e0165441.","journal-title":"PLoS One"},{"key":"2937_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1067\/mem.2002.122706","volume":"39","author":"C Ramsook","year":"2002","unstructured":"Ramsook C, Sahagun-Carreon I, Kozinetz CA, Moro-Sutherland D. A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med. 2002;39:397\u2013403.","journal-title":"Ann Emerg Med"},{"key":"2937_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/PEC.0000000000000757","volume":"34","author":"SK Krammes","year":"2018","unstructured":"Krammes SK, Jacobs T, Clark JM, Lutes RE. Effect of intravenous Ondansetron on the QT interval of Patients' electrocardiograms. Pediatr Emerg Care. 2018;34:38\u201341.","journal-title":"Pediatr Emerg Care"},{"key":"2937_CR10","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.ajem.2017.10.004","volume":"36","author":"RJ Hoffman","year":"2018","unstructured":"Hoffman RJ, Alansari K. Effect of intravenous ondansetron on QTc interval in children with gastroenteritis. Am J Emerg Med. 2018;36:754\u20137.","journal-title":"Am J Emerg Med"},{"key":"2937_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.annemergmed.2013.10.026","volume":"64","author":"SB Freedman","year":"2014","unstructured":"Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014;64:19\u201325.e6.","journal-title":"Ann Emerg Med"},{"key":"2937_CR12","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/jcph.322","volume":"54","author":"P Zuo","year":"2014","unstructured":"Zuo P, Haberer LJ, Fang L, Hunt TL, Ridgway D, Russo MW. Integration of modeling and simulation to support changes to ondansetron dosing following a randomized, double-blind, placebo-, and active-controlled thorough QT study. J Clin Pharmacol. 2014;54:1221\u20139.","journal-title":"J Clin Pharmacol"},{"key":"2937_CR13","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1097\/PEC.0b013e3182717358","volume":"28","author":"D Hervas","year":"2012","unstructured":"Hervas D, Armero C, Carrion T, Utrera JF, Hervas JA. Clinical and economic impact of oral ondansetron for vomiting in a pediatric emergency department. Pediatr Emerg Care. 2012;28:1166\u20138.","journal-title":"Pediatr Emerg Care"},{"issue":"2","key":"2937_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jpeds.2004.05.035","volume":"145","author":"JN Friedman","year":"2004","unstructured":"Friedman JN, Goldman RD, Srivastava R, Parkin PC. Development of a clinical dehydration scale for use in children between 1 and 36 months of age. J Pediatr. 2004;145(2):201\u20137.","journal-title":"J Pediatr"},{"key":"2937_CR15","unstructured":"Food, Drug Administration USDoH, Human S. Guidance for Industry. E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. https:\/\/www.fda.gov\/media\/71372\/download. Updated October 2005.\u00a0Accessed 20 Oct 2019."},{"key":"2937_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1540-8167.2006.00408.x","volume":"17","author":"I Goldenberg","year":"2006","unstructured":"Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is \"normal\". J Cardiovasc Electrophysiol. 2006;17:333\u20136.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2937_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1161\/01.CIR.6.3.378","volume":"6","author":"E Lepeschkin","year":"1952","unstructured":"Lepeschkin E, Surawicz B. The measurement of the Q-T interval of the electrocardiogram. Circulation. 1952;6:378\u201388.","journal-title":"Circulation."},{"key":"2937_CR18","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1097\/PCC.0000000000000776","volume":"17","author":"S Trivedi","year":"2016","unstructured":"Trivedi S, Schiltz B, Kanipakam R, Bos JM, Ackerman MJ, Ouellette Y. Effect of Ondansetron on QT interval in patients cared for in the PICU. Pediatr Crit Care Med. 2016;17:e317\u201323.","journal-title":"Pediatr Crit Care Med"},{"key":"2937_CR19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jemermed.2009.08.060","volume":"39","author":"AE Patanwala","year":"2010","unstructured":"Patanwala AE, Amini R, Hays DP, Rosen P. Antiemetic therapy for nausea and vomiting in the emergency department. J Emerg Med. 2010;39:330\u20136.","journal-title":"J Emerg Med"},{"key":"2937_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/acem.12836","volume":"23","author":"PM Moffett","year":"2016","unstructured":"Moffett PM, Cartwright L, Grossart EA, O'Keefe D, Kang CS. Intravenous Ondansetron and the QT interval in adult emergency department patients: an observational study. Acad Emerg Med. 2016;23:102\u20135.","journal-title":"Acad Emerg Med"},{"key":"2937_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2165\/00003088-199529020-00004","volume":"29","author":"F Roila","year":"1995","unstructured":"Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet. 1995;29:95\u2013109.","journal-title":"Clin Pharmacokinet"},{"key":"2937_CR22","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1460-9592.2010.03408.x","volume":"20","author":"D Mehta","year":"2010","unstructured":"Mehta D, Sanatani S, Whyte SD. The effects of droperidol and ondansetron on dispersion of myocardial repolarization in children. Paediatr Anaesth. 2010;20:905\u201312.","journal-title":"Paediatr Anaesth"},{"key":"2937_CR23","doi-asserted-by":"crossref","unstructured":"Freedman SB, Soofi SB, Willan AR, Williamson-Urquhart S, Siddiqui E, Xie J, et al. Oral Ondansetron Administration to Dehydrated Children in Pakistan: A Randomized Clinical Trial. Pediatrics. 2019;144(6):e20192161.","DOI":"10.1542\/peds.2019-2161"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-021-02937-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-021-02937-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-021-02937-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T08:04:20Z","timestamp":1636531460000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-021-02937-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2937"],"URL":"https:\/\/doi.org\/10.1186\/s12887-021-02937-0","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"assertion":[{"value":"4 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving research study participants were approved by the Ajou Medical Center Institutional Review Board (approval number AJIRB-MED-MDB-20-123). Because of the study\u2019s retrospective nature, Ajou Medical Center Institutional Review Board specifically waived the requirement to obtain parental or guardian informed consent to conduct this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"501"}}